EP Patent

EP3266455A2 — Composition for prevention or treatment of intractable epilepsy comprising mtor inhibitor

Assigned to Korea Advanced Institute of Science and Technology KAIST · Expires 2018-01-10 · 8y expired

What this patent protects

Provided is a use of the prophylaxis, amelioration or therapy of intractable epilepsy, for example, Focal Cortical Dysplasia (FCD).

USPTO Abstract

Provided is a use of the prophylaxis, amelioration or therapy of intractable epilepsy, for example, Focal Cortical Dysplasia (FCD).

Drugs covered by this patent

Patent Metadata

Patent number
EP3266455A2
Jurisdiction
EP
Classification
—
Expires
2018-01-10
Drug substance claim
No
Drug product claim
No
Assignee
Korea Advanced Institute of Science and Technology KAIST
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.